Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : Ubiquigent
Deal Size : Undisclosed
Deal Type : Agreement
Ubiquigent Enters Agreement with Astellas Subsidiary, Nanna Therapeutics
Details : Ubiquigent will provide Nanna access to its deubiquitylase (DUB) platform to support novel therapeutics development for selected human disease targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 11, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Ubiquigent
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : Astellas Pharma
Deal Size : $98.5 million
Deal Type : Acquisition
Astellas Announces Acquisition of Nanna
Details : Adding Nanna’s proprietary and advanced screening platform with new DNA-encoded chemical libraries (DELs) technology significantly bolsters Astellas’ early stage drug development capabilities.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $17.0 million
April 21, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : Astellas Pharma
Deal Size : $98.5 million
Deal Type : Acquisition
Reset All
